Bednarík J, Kadanka Z
Neurologická klinika LF MU a FN, Brno-Bohunice.
Cas Lek Cesk. 1999 Nov 1;138(21):647-9.
Treatment with intravenous human immunoglobulin (IVIG) has become a routine therapeutic method in immunodeficiency states and autoimmune diseases. Although it is a relatively safe therapeutic method it may have serious undesirable effects. Knowledge of these undesirable effects is the prerequisite for coping with them and in some instances it is possible to prevent them. Undesirable effects of IVIG administration can be divided into six groups: 1. Generalized reaction, in particular fever, shiver, nausea, vomiting, tachycardia, dyspnoea, changes of blood pressure are recorded in less than 5% patients, usually during infusion and depend on the rate of administration. 2. Hypersensitivity and anaphylactic reactions may be also severe to fatal and are usually the manifestation of the action of antibodies against IgA; they may be anticipated in particular in patients with deficiency of class A immunoglobulins and in patients with autoimmune diseases. 3. Haematological: rare and usually clinically irrelevant haemolytic anaemia. 4. Neurological: frequent and minor headache, rarely relapsing aseptic meningitis syndrome. 5. Nephrological: renal failure which developed by the mechanism of osmotic nephrosis, relatively very rare, affecting almost exclusively patients with nephropathy present before administration of IVIG. 6. Thrombotic complications manifested by cerebral ischaemia. They are however extremely rare and their relationship to IVIG administration is controversial. At present we can rule out transmission of viral infection by IVIG preparations with the exception of transmission of the hepatitis C virus.
静脉注射用人免疫球蛋白(IVIG)治疗已成为免疫缺陷状态和自身免疫性疾病的常规治疗方法。尽管它是一种相对安全的治疗方法,但可能会产生严重的不良影响。了解这些不良影响是应对它们的前提,在某些情况下还可以预防。IVIG给药的不良影响可分为六组:1.全身反应,特别是发热、寒战、恶心、呕吐、心动过速、呼吸困难、血压变化,不到5%的患者会出现,通常在输注过程中出现,且取决于给药速度。2.超敏反应和过敏反应也可能严重甚至致命,通常是抗IgA抗体作用的表现;尤其在A类免疫球蛋白缺乏的患者和自身免疫性疾病患者中可能会出现。3.血液学方面:罕见且通常临床意义不大的溶血性贫血。4.神经学方面:常见的轻微头痛,罕见的复发性无菌性脑膜炎综合征。5.肾脏病学方面:由渗透性肾病机制导致的肾衰竭,相对非常罕见,几乎只影响在IVIG给药前就患有肾病的患者。6.血栓形成并发症表现为脑缺血。然而,它们极其罕见,其与IVIG给药的关系存在争议。目前,除丙型肝炎病毒传播外,我们可以排除IVIG制剂传播病毒感染的可能性。